ARTICLE | Clinical News
SSR125543: Phase II discontinued
May 2, 2011 7:00 AM UTC
sanofi-aventis disclosed in its 1Q11 earnings that it discontinued the double-blind, international Phase II AGATE trial of SSR125543 in patients with MDD after the compound missed the primary endpoint...